BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 29 Jun, 3:58PM

41.53

0.02 (0.05%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Bristol-Myers Squibb Company Bearish Bearish

Stockmoo Score

1.0

Similar Stocks

Stock Market Cap DY P/E P/B
BMY 84 B 5.71% - 5.95
JNJ 396 B 2.96% 24.83 5.53
ABBV 285 B 2.84% 48.13 50.39
PFE 162 B 5.85% - 1.85
LLY 864 B 0.52% 117.65 60.60
MRK 320 B 2.40% 140.50 6.89

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
52 Weeks Range
39.63 (-4%) — 65.38 (57%)
Price Target Range
42.00 (1%) — 53.00 (27%)
High 53.00 (TD Cowen, 27.62%) Hold
Median 45.00 (8.36%)
Low 42.00 (Barclays, 1.13%) Sell
Average 47.20 (13.65%)
Total 4 Hold, 1 Sell
Avg. Price @ Call 45.88
Firm Date Target Price Call Price @ Call
Jefferies 28 Aug 2024 51.00 (22.80%) Hold 49.06
Barclays 22 Aug 2024 42.00 (1.13%) Sell 47.62
29 Jul 2024 41.00 (-1.28%) Sell 48.98
TD Cowen 12 Aug 2024 53.00 (27.62%) Hold 47.06
Deutsche Bank 23 Jul 2024 45.00 (8.36%) Hold 42.98
Cantor Fitzgerald 22 Jul 2024 45.00 (8.36%) Hold 42.67

No data within this time range.

  • 3M
Date Type Details
06 Sep 2024 Announcement Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
01 Sep 2024 Announcement Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
27 Aug 2024 Announcement Bristol Myers Squibb to Participate in Upcoming Investor Conferences
26 Aug 2024 Announcement Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
21 Aug 2024 Announcement Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
19 Aug 2024 Announcement European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
15 Aug 2024 CNBC Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year
15 Aug 2024 CNBC What's next for the Biden administration's Medicare drug price negotiations
06 Aug 2024 CNBC Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare
26 Jul 2024 Announcement Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
26 Jul 2024 CNBC Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 
19 Jul 2024 Announcement Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
08 Jul 2024 Announcement Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
28 Jun 2024 CNBC Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
26 Jun 2024 CNBC Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers
21 Jun 2024 Announcement European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
21 Jun 2024 Announcement Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
20 Jun 2024 Announcement Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
18 Jun 2024 Announcement Bristol Myers Squibb Announces Dividend
18 Jun 2024 Announcement Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
13 Jun 2024 Announcement U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Show more
TTM Dividend Yield 5.71%
5Y Average Dividend Yield 3.21%
Expected Next Dividend Payment Nov 2024
Ex Date Announcement Date Payment Date Details
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Cash
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Cash
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Cash
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Cash
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Cash
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Cash
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Cash
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Cash
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Cash
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Cash
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Cash
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Cash
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Cash
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Cash
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Cash
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Cash
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Cash
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Cash
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Cash
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Cash
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Cash
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Cash
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Cash
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Cash
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Cash
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Cash
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Cash
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Cash
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Cash
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Cash
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Cash
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Cash
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Cash
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Cash
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Cash
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Cash
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Cash
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Cash
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Cash
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Cash
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Cash
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Cash
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Cash
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Cash
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 1.80 3 4.33
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria